VERTEX PHARMACEUTICALS INC / MA Unrealized Gain (Loss) on Investments
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Unrealized Gain (Loss) on Investments of -$8.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA unrealized gain (loss) on investments for the quarter ending 2026-06-30 was -$8.50M, a 232.81% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA unrealized gain (loss) on investments for the quarter ending 2026-03-31 was $3.80M.
- VERTEX PHARMACEUTICALS INC / MA unrealized gain (loss) on investments for the quarter ending 2025-12-31 was $7.30M, a 135.48% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA unrealized gain (loss) on investments for the quarter ending 2025-09-30 was -$1.50M, a 153.57% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA unrealized gain (loss) on investments for fiscal 2025 was -$11.30M.
- VERTEX PHARMACEUTICALS INC / MA unrealized gain (loss) on investments for fiscal 2024 was -$9.50M.
- VERTEX PHARMACEUTICALS INC / MA unrealized gain (loss) on investments for fiscal 2023 was -$7.50M.
- VERTEX PHARMACEUTICALS INC / MA unrealized gain (loss) on investments for fiscal 2022 was -$149.10M, a 971.93% decline from fiscal 2021.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 3 month as first filed | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 6 month as first filed | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 9 month as first filed | Unrealized Gain (Loss) on Investments 12 month | Unrealized Gain (Loss) on Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.50M 10-Q · filed 2026-08-04 | -$4.70M 10-Q · filed 2026-08-04 | $2.60M derived: sum of 3 quarters · filed 2026-08-04 | $1.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $3.80M 10-Q · filed 2026-05-05 | $11.10M derived: sum of 2 quarters · filed 2026-05-05 | $9.60M derived: sum of 3 quarters · filed 2026-05-05 | $16.00M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $5.80M derived: sum of 2 quarters · filed 2026-02-13 | $12.20M derived: sum of 3 quarters · filed 2026-08-04 | -$11.30M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | -$1.50M 10-Q · filed 2025-11-04 | $4.90M derived: sum of 2 quarters · filed 2026-08-04 | -$18.60M 10-Q · filed 2025-11-04 | -$7.00M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $6.40M 10-Q · filed 2026-08-04 | -$8.60M 10-Q · filed 2026-08-04 | -$5.50M derived: sum of 3 quarters · filed 2026-08-04 | -$2.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$15.00M 10-Q · filed 2026-05-05 | -$11.90M derived: sum of 2 quarters · filed 2026-05-05 | -$9.10M derived: sum of 3 quarters · filed 2026-05-05 | -$21.80M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $5.90M derived: sum of 2 quarters · filed 2026-02-13 | -$6.80M derived: sum of 3 quarters · filed 2026-02-13 | -$9.50M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $2.80M 10-Q · filed 2025-11-04 | -$9.90M derived: sum of 2 quarters · filed 2025-11-04 | -$12.60M 10-Q · filed 2025-11-04 | -$13.00M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | -$12.70M 10-Q · filed 2025-08-05 | -$15.40M 10-Q · filed 2025-08-05 | -$15.80M derived: sum of 3 quarters · filed 2026-02-13 | -$22.00M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | -$2.70M 10-Q · filed 2025-05-06 | -$3.10M derived: sum of 2 quarters · filed 2026-02-13 | -$9.30M derived: sum of 3 quarters · filed 2026-02-13 | -$100.00K derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$6.60M derived: sum of 2 quarters · filed 2026-02-13 | $2.60M derived: sum of 3 quarters · filed 2026-02-13 | -$7.50M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | -$6.20M 10-Q · filed 2024-11-05 | $3.00M derived: sum of 2 quarters · filed 2024-11-05 | -$7.10M 10-Q · filed 2024-11-05 | $3.40M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $9.20M 10-Q · filed 2024-08-02 | -$900.00K 10-Q · filed 2024-08-02 | $9.60M derived: sum of 3 quarters · filed 2025-02-13 | $26.30M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $6.40M 10-Q · filed 2024-05-07 | $400.00K derived: sum of 2 quarters · filed 2025-02-13 | $17.10M derived: sum of 3 quarters · filed 2025-02-13 | -$67.10M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $10.70M derived: sum of 2 quarters · filed 2025-02-13 | -$73.50M derived: sum of 3 quarters · filed 2025-02-13 | -$149.10M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $16.70M 10-Q · filed 2023-11-07 | -$67.50M derived: sum of 2 quarters · filed 2023-11-07 | -$143.10M 10-Q · filed 2023-11-07 | -$131.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | -$84.20M 10-Q · filed 2023-08-02 | -$159.80M 10-Q · filed 2023-08-02 | -$147.70M derived: sum of 3 quarters · filed 2024-02-15 | -$101.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | -$75.60M 10-Q · filed 2023-05-02 | -$63.50M derived: sum of 2 quarters · filed 2024-02-15 | -$16.80M derived: sum of 3 quarters · filed 2024-02-15 | -$6.20M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $58.80M derived: sum of 2 quarters · filed 2024-02-15 | $69.40M derived: sum of 3 quarters · filed 2024-02-15 | $17.10M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $46.70M 10-Q · filed 2022-10-28 | $46.68M 10-Q · filed 2021-11-03 | $57.30M derived: sum of 2 quarters · filed 2022-10-28 | $5.00M 10-Q · filed 2022-10-28 | $4.99M 10-Q · filed 2021-11-03 | $38.88M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-06-30 | $10.60M 10-Q · filed 2022-08-05 | $10.61M 10-Q · filed 2021-07-30 | -$41.70M 10-Q · filed 2022-08-05 | -$41.69M 10-Q · filed 2021-07-30 | -$7.82M derived: sum of 3 quarters · filed 2023-02-10 | $62.02M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-03-31 | -$52.30M 10-Q · filed 2022-05-06 | -$52.30M 10-Q · filed 2021-04-30 | -$18.42M derived: sum of 2 quarters · filed 2023-02-10 | $51.42M derived: sum of 3 quarters · filed 2023-02-10 | $136.93M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $33.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $103.72M derived: sum of 2 quarters · filed 2023-02-10 | $189.23M derived: sum of 3 quarters · filed 2023-02-10 | $136.20M 10-K · filed 2023-02-10 | $136.17M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $69.83M 10-Q · filed 2021-11-03 | $69.80M 10-Q · filed 2020-10-30 | $155.34M derived: sum of 2 quarters · filed 2021-11-03 | $102.32M 10-Q · filed 2021-11-03 | $102.30M 10-Q · filed 2020-10-30 | $190.21M derived: sum of 4 quarters · filed 2022-02-09 | ||
| 2020-06-30 | $85.51M 10-Q · filed 2021-07-30 | $85.50M 10-Q · filed 2020-07-31 | $35.19M 10-Q · filed 2021-07-30 | $35.20M 10-Q · filed 2020-07-31 | $120.37M derived: sum of 3 quarters · filed 2022-02-09 | $89.17M derived: sum of 4 quarters · filed 2022-02-09 | ||
| 2020-03-31 | -$39.44M 10-Q · filed 2021-04-30 | -$39.40M 10-Q · filed 2020-05-01 | $34.86M derived: sum of 2 quarters · filed 2022-02-09 | $3.66M derived: sum of 3 quarters · filed 2022-02-09 | $60.16M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2019-12-31 | $74.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $43.10M derived: sum of 2 quarters · filed 2022-02-09 | $99.60M derived: sum of 3 quarters · filed 2022-02-09 | $143.20M 10-K · filed 2022-02-09 | $132.50M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | -$31.20M 10-Q · filed 2020-10-30 | $25.30M derived: sum of 2 quarters · filed 2020-10-30 | $68.90M 10-Q · filed 2020-10-30 | -$16.74M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $56.50M 10-Q · filed 2020-07-31 | $100.10M 10-Q · filed 2020-07-31 | $14.46M derived: sum of 3 quarters · filed 2021-02-11 | -$46.74M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $43.60M 10-Q · filed 2020-05-01 | -$42.04M derived: sum of 2 quarters · filed 2021-02-11 | -$103.24M derived: sum of 3 quarters · filed 2021-02-11 | -$49.34M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | -$85.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$146.84M derived: sum of 2 quarters · filed 2021-02-11 | -$92.94M derived: sum of 3 quarters · filed 2021-02-11 | $2.56M 10-K · filed 2021-02-11 | $2.60M 10-K · filed 2019-02-13 | |||
| 2018-09-30 | -$61.20M 10-Q · filed 2019-10-31 | -$7.30M derived: sum of 2 quarters · filed 2019-10-31 | $88.20M 10-Q · filed 2019-10-31 | |||||
| 2018-06-30 | $53.90M 10-Q · filed 2019-08-01 | $149.40M 10-Q · filed 2019-08-01 | ||||||
| 2018-03-31 | $95.50M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |